Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX NASDAQ:GUTS NASDAQ:NVNO NASDAQ:NXGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$2.26-0.9%$1.86$0.76▼$2.73$85.41M1.3185,906 shs39,380 shsGUTSFractyl Health$1.79$1.82$0.87▼$4.37$87.67M1.58372,579 shs325,995 shsNVNOenVVeno Medical$4.97-5.3%$3.99$2.03▼$5.92$87.15M0.93116,152 shs360,024 shsNXGLNexGel$2.42+1.3%$2.42$2.10▼$5.10$18.52M0.5971,920 shs40,537 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical0.00%+7.62%+32.16%+128.28%+63.77%GUTSFractyl Health0.00%+17.76%-6.28%+46.72%-62.08%NVNOenVVeno Medical0.00%+18.90%+20.34%+102.86%-16.47%NXGLNexGel0.00%-7.81%+0.41%-14.49%+14.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical1.8362 of 5 stars0.04.00.04.20.01.70.6GUTSFractyl Health2.2047 of 5 stars3.53.00.00.01.80.00.0NVNOenVVeno MedicalN/AN/AN/AN/AN/AN/AN/AN/ANXGLNexGel0.7229 of 5 stars0.03.00.00.01.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate BuyN/AN/AGUTSFractyl Health 3.00Buy$11.00514.53% UpsideNVNOenVVeno Medical 0.00N/AN/AN/ANXGLNexGel 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$47.29M1.81N/AN/A$0.38 per share5.95GUTSFractyl Health$90K974.16N/AN/A$0.59 per share3.03NVNOenVVeno MedicalN/AN/AN/AN/A$2.40 per shareN/ANXGLNexGel$10.23M1.81N/AN/A$0.90 per share2.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$23.46M-$0.55N/AN/AN/A-42.37%-156.85%-31.92%8/6/2025 (Estimated)GUTSFractyl Health-$68.69M-$1.85N/AN/AN/A-73,864.52%-228.66%-76.74%8/13/2025 (Estimated)NVNOenVVeno Medical-$21.82M-$1.18N/AN/AN/AN/A-51.32%-48.23%7/30/2025 (Estimated)NXGLNexGel-$3.28M-$0.45N/A∞N/A-30.80%-54.95%-27.84%8/18/2025 (Estimated)Latest NXGL, APYX, GUTS, and NVNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025GUTSFractyl Health-$0.37N/AN/AN/AN/AN/A7/30/2025N/ANVNOenVVeno Medical-$0.28N/AN/AN/AN/AN/A5/13/2025Q1 2025GUTSFractyl Health-$0.49-$0.49N/A-$0.49N/AN/A5/13/2025Q1 2025NXGLNexGel-$0.10-$0.09+$0.01-$0.09$2.73 million$2.81 million5/8/2025Q1 2025APYXApyx Medical-$0.13-$0.10+$0.03-$0.10$9.39 million$9.43 million4/30/2025Q1 2025NVNOenVVeno MedicalN/A-$0.22N/A-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/AGUTSFractyl HealthN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ANXGLNexGelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical3.215.454.64GUTSFractyl Health4.612.502.50NVNOenVVeno MedicalN/A23.7723.77NXGLNexGel0.151.881.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%GUTSFractyl HealthN/ANVNOenVVeno Medical34.71%NXGLNexGel2.21%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%GUTSFractyl HealthN/ANVNOenVVeno Medical16.00%NXGLNexGel20.55%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.79 million32.05 millionOptionableGUTSFractyl Health10248.98 millionN/AN/ANVNOenVVeno Medical3017.54 million14.73 millionOptionableNXGLNexGel107.66 million6.08 millionNot OptionableNXGL, APYX, GUTS, and NVNO HeadlinesRecent News About These CompaniesNEXGEL Expands Partnership With STADA, Secures $1 Million to Fuel New Product LaunchesJuly 17 at 8:17 AM | msn.comNEXGEL and STADA AG Announce Expansion of Partnership for North AmericaJuly 14, 2025 | globenewswire.comNexGel Inc Stockholders Approve Key Proposals at MeetingJune 20, 2025 | tipranks.comNEXGEL to Participate in the 6th Annual CEO Networking Event Hosted by Semco Capital on June 2ndMay 21, 2025 | finance.yahoo.comEarnings call transcript: Nexgel’s Q1 2025 results show growth, future optimismMay 15, 2025 | uk.investing.comNEXGEL, Inc. (NASDAQ:NXGL) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comNEXGEL, Inc. (NXGL) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comNEXGEL Reports First Quarter 2025 Financial ResultsMay 13, 2025 | taiwannews.com.twT1NXGL : A Peek at NexGel's Future EarningsMay 12, 2025 | benzinga.comNEXGEL to Announce Q1 2025 Financial Results on May 13May 12, 2025 | msn.comNEXGEL, Inc. to Release First Quarter 2025 Financial Results and Host Conference Call on May 13, 2025May 9, 2025 | quiverquant.comQNEXGEL to Report First Quarter 2025 Financial Results on May 13thMay 9, 2025 | globenewswire.comNEXGEL CEO Adam Levy to Present at Planet MicroCap Showcase 2025April 9, 2025 | msn.comNEXGEL to Present at the Planet MicroCap Showcase in Las Vegas, NV April 22nd-24thApril 7, 2025 | markets.businessinsider.comAdam R. Levy Sells 4,000 Shares of NEXGEL, Inc. (NASDAQ:NXGL) StockApril 3, 2025 | insidertrades.comNEXGEL Reports Record-Breaking 2024 Financial PerformanceMarch 27, 2025 | msn.comNEXGEL, Inc. (NASDAQ:NXGL) Q4 2024 Earnings Call TranscriptMarch 26, 2025 | insidermonkey.comEarnings call transcript: Nexgel Q4 2024 sees revenue surge, stock jumpsMarch 26, 2025 | investing.comNEXGEL, Inc. Reports Record Q4 and Full Year 2024 Revenue Growth of 181% and 112% Respectively, Forecasts $13 Million in Revenue for 2025March 26, 2025 | nasdaq.comNEXGEL Reports Record Revenue Growth in 2024March 24, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXGL, APYX, GUTS, and NVNO Company DescriptionsApyx Medical NASDAQ:APYX$2.26 -0.02 (-0.88%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.27 +0.01 (+0.44%) As of 07/18/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Fractyl Health NASDAQ:GUTS$1.79 0.00 (0.00%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.82 +0.02 (+1.40%) As of 07/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.enVVeno Medical NASDAQ:NVNO$4.97 -0.28 (-5.33%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$5.04 +0.08 (+1.51%) As of 07/18/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. NexGel NASDAQ:NXGL$2.42 +0.03 (+1.26%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$2.42 0.00 (0.00%) As of 07/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
